Injury Prevention is a peer-reviewed academic journal published by the prestigious BMJ Publishing Group, dedicated to advancing the field of public health, especially in the realm of preventing injuries. With an ISSN of 1353-8047 and an E-ISSN of 1475-5785, this journal stands out as a critical resource within its domain, reflecting its significant impact as evidenced by its Q1 ranking in Public Health, Environmental and Occupational Health, according to the latest 2023 metrics. Covering a wide array of topics from epidemiology to policy implications, Injury Prevention fosters the exchange of innovative research and effective strategies to reduce injuries on a global scale. The journal has been published continuously since 1995 and will continue its commitment to excellence through 2024. Researchers, professionals, and students alike will benefit from its rich content that reflects current trends and advancements in injury prevention methodologies. Although it currently does not offer Open Access options, its high ranking, with a Scopus rank of #170 out of 665 in its category and sitting at the 74th percentile, underscores its importance in informing and influencing best practices for public health initiatives worldwide. For those looking to contribute to or stay informed on critical advancements in the field, Injury Prevention remains an indispensable resource.

The Journal of Cancer Epidemiology, published by HINDAWI LTD, is a premier open access journal that has been disseminating vital research findings since 2008. With ISSN 1687-8558 and E-ISSN 1687-8566, this journal is dedicated to enhancing our understanding of cancer's epidemiological factors, thereby fostering advancements in public health, genetics, and environmental health. The journal's current quartile ranking places it in Q3 for Epidemiology and Public Health, as well as Q4 for Genetics, reflecting its growing influence in these fields. As of 2023, it holds respectable Scopus rankings, including a rank of #73 in Epidemiology, positioning it within the 51st percentile. Based in the United States with an address in London, this journal represents a crucial platform for researchers, professionals, and students eager to contribute to the global fight against cancer. For those passionate about uncovering insights into cancer risk factors and trends, the Journal of Cancer Epidemiology offers a comprehensive repository of high-quality research accessible to all.

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

Cancer Epidemiology, published by ELSEVIER SCI LTD, serves as a premier platform for disseminating innovative research in the areas of cancer epidemiology and oncology. Operating from the Netherlands, this journal provides a critical insight into the factors influencing cancer incidence, including genetic, environmental, and lifestyle variables. With an impact factor reflecting its significance in the field, it holds a respectable Q2 ranking in Cancer Research, Epidemiology, and Oncology. The journal spans a wide range of topics and publishes studies that aim to bridge gaps in existing literature through rigorous research methodologies. Researchers and professionals interested in acquiring the latest insights and contributing to the evolving discourse on cancer epidemiology will find this journal an invaluable resource. Access to articles may be available through open access options, ensuring the widest dissemination of knowledge.

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

HYPERTENSION RESEARCH, published by SpringerNature, serves as a premier platform in the field of Cardiology and Cardiovascular Medicine, Internal Medicine, and Physiology. Since its inception in 1992, the journal has built a substantial reputation, currently ranked in the second quartile (Q2) across several categories in 2023, reflecting its influence and high-quality contributions to medical research. With a focus on hypertension, the journal aims to disseminate vital research findings, clinical studies, and innovative treatment strategies to a diverse audience of researchers, healthcare professionals, and students, fostering knowledge exchange in the management of hypertensive conditions. Although it is not an Open Access journal, it offers comprehensive access to its extensive archive of valuable resources, ensuring that critical advancements in the understanding of hypertension are both accessible and impactful. HYPERTENSION RESEARCH is not only essential for those directly involved in cardiovascular and internal medicine practices but also for interdisciplinary scholars who are looking to explore the intersections of physiology and other biomedical fields in their work.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.